HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Electronegative very-low-density lipoprotein induces brain inflammation and cognitive dysfunction in mice.

Abstract
Epidemiologic studies have indicated that dyslipidemia may facilitate the progression of cognitive dysfunction. We previously showed that patients with metabolic syndrome (MetS) had significantly higher plasma levels of electronegative very-low-density lipoprotein (VLDL) than did healthy controls. However, the effects of electronegative-VLDL on the brain and cognitive function remain unclear. In this study, VLDL isolated from healthy volunteers (nVLDL) or patients with MetS (metVLDL) was administered to mice by means of tail vein injection. Cognitive function was assessed by using the Y maze test, and plasma and brain tissues were analyzed. We found that mice injected with metVLDL but not nVLDL exhibited significant hippocampus CA3 neuronal cell loss and cognitive dysfunction. In mice injected with nVLDL, we observed mild glial cell activation in the medial prefrontal cortex (mPFC) and hippocampus CA3. However, in mice injected with metVLDL, plasma and brain TNF-α and Aβ-42 levels and glial cell activation in the mPFC and whole hippocampus were higher than those in control mice. In conclusion, long-term exposure to metVLDL induced levels of TNF-α, Aβ-42, and glial cells in the brain, contributing to the progression of cognitive dysfunction. Our findings suggest that electronegative-VLDL levels may represent a new therapeutic target for cognitive dysfunction.
AuthorsYing-Shao Lin, Ching-Kuan Liu, Hsiang-Chun Lee, Mei-Chuan Chou, Liang-Yin Ke, Chu-Huang Chen, Shiou-Lan Chen
JournalScientific reports (Sci Rep) Vol. 11 Issue 1 Pg. 6013 (03 16 2021) ISSN: 2045-2322 [Electronic] England
PMID33727609 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Lipoproteins, VLDL
Topics
  • Animals
  • CA3 Region, Hippocampal (metabolism, pathology)
  • Cognitive Dysfunction (chemically induced, metabolism, pathology)
  • Dyslipidemias (metabolism)
  • Humans
  • Inflammation (chemically induced, metabolism, pathology)
  • Lipoproteins, VLDL (metabolism, toxicity)
  • Male
  • Metabolic Syndrome (metabolism)
  • Mice
  • Prefrontal Cortex (metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: